| Literature DB >> 23990987 |
Qiong Jia1, Qian Zhang, Zhaojun Zhang, Yaqin Wang, Wanguang Zhang, Yang Zhou, Yang Wan, Tao Cheng, Xiaofan Zhu, Xiangdong Fang, Weiping Yuan, Haibo Jia.
Abstract
Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome that is characterized by pure red-cell aplasia and associated physical deformities. It has been proven that defects of ribosomal proteins can lead to this disease and that RPS19 is the most frequently mutated gene in DBA patients. Previous studies suggest that p53-dependent genes and pathways play important roles in RPS19-deficient embryos. However, whether there are other vital factors linked to DBA has not been fully clarified. In this study, we compared the whole genome RNA-Seq data of zebrafish embryos injected with RPS19 morpholino (RPS19 MO), RPS19 and p53 morpholino simultaneously (RPS19+p53 MO) and control morpholino (control). We found that genes enriched in the functions of hematological systems, nervous system development and skeletal and muscular disorders had significant differential expression in RPS19 MO embryos compared with controls. Co-inhibition of p53 partially alleviates the abnormalities for RPS19-deficient embryos. However, the hematopoietic genes, which were down-regulated significantly in RPS19 MO embryos, were not completely recovered by the co-inhibition of p53. Furthermore, we identified the genome-wide p53-dependent and -independent genes and pathways. These results indicate that not only p53 family members but also other factors have important impacts on RPS19-deficient embryos. The detection of potential pathogenic genes and pathways provides us a new paradigm for future research on DBA, which is a systematic and complex hereditary disease.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23990987 PMCID: PMC3747179 DOI: 10.1371/journal.pone.0071782
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Effectiveness of RPS19 morpholinos and hemoglobin staining of embryos coinjected with Rps19 mRNA and P53 MO using o-dianisidine.
The Rps19:egfp construct was made by inserting a partial sequence of Rps19 cDNA (containing 60 bps from the 5′ UTR ) with the N-terminus of egfp into modified pEGFP-N1 (the ATG codon of EGFP was removed). The sequence of RPS19 MO1 is a compliment of bp 1–24 of Rps19 cDNA. Embryos co-injected with 25 ng Rps19:egfp DNA and 5 ng control MO produced green fluorescent fusion protein (A), and expression of the fusion protein was inhibited by co-injection with 2 ng Rps19 Mo (B). O-staining results show a drastic reduction in the number of hemoglobin-stained blood cells when Rps19 is knockdown (C and D are the control, E and F are Rps19 knockdown) and partially reversed by co-injection of P53 morpholino (G and H). A, B, D, F and H are the lateral view; C, E and G are the ventral view.
Figure 2Overview of gene expression profiles of diverse zebrafish embryos.
(A) Venn diagram detailing shared and distinct genes expression among three zebrafish embryo samples: control morpholino (control), RPS19 morpholino knockdown (RPS19 MO), RPS19 and p53 morpholino knockdown simultaneously (RPS19+p53 MO). (B)Unsupervised clustering of genome-wide gene expression (cutoff FPKM<1) for diverse zebrafish embryos (control morpholino (control), RPS19 morpholino knockdown (RPS19 MO), RPS19 and p53 morpholino knockdown simultaneously (RPS19+p53 MO)). Gene expression tracks use red and green to represent over- and under-expression, respectively. The pattern of the transcriptome profile of RPS19 MO is more similar to that of RPS19+p53 MO.
Figure 3The top enriched biological functions of 359 differentially expressed genes in RPS19-deficient embryos (p-value<0.05).
Figure 4Top networks identified with IPA for the differentially expressed genes in RPS19 MO compared with the control.
The pink or red nodes in the networks indicate a gene that is up-regulated in RPS19 MO, and the green color indicates genes that are down-regulated in RPS19 MO. (A) Network with the functions of embryonic development, organismal development, and cellular development. (B) Network with the functions of digestive system development and function, developmental disorder, and skeletal and muscular disorders. (C) Network with the functions of hematological system development and function, organismal functions, and cellular movement. (D) Network with the functions of nervous system development and function, tissue morphology, and cell-to-cell signaling and interaction.
Figure 5The top enriched biological functions of 147 differentially expressed genes in RPS19-deficient embryos with co-inhibition of p53 (p-value<0.05).
Figure 6Top networks identified with IPA for the differentially expressed genes in RPS19+p53 MO compared with the control.
The pink or red nodes in the networks indicate genes that are up-regulated in RPS19+p53 MO, and the green color indicates genes that are down-regulated in RPS19+p53 MO. (A) Network with the functions of lipid metabolism, molecular transport, and small molecule biochemistry. (B) Network with the functions of cell cycle, cellular development, cellular growth and proliferation. (C) Network with the functions of cancer, hematological disease, and amino acid metabolism. (D) Network with the functions of cellular development, hematological system development and function, and hematopoiesis.
Figure 7The scheme of detection of p53 dependent and independent genes.
The vertical axis represents the gene expression, which is normalized to FPKM. The red arrows indicate the variation trend of FPKM for abnormal up-regulated genes in RPS19 MO, and the green arrows indicate the down-regulated genes in RPS19 MO. Solid arrows indicate the variation trend of FPKM of genes in RPS19 MO, and dashed arrows indicate the variation trend of FPKM of genes in RPS19+p53 MO. Up−/down-regulated genes are screened with the criterion of a fold-change of >2.0 and a p-value of <0.05. (A) Up−/down-regulated genes in RPS19 MO compared with the control and down−/up-regulated genes in RPS19+p53 MO compared with RPS19 MO; we considered genes that satisfied the above criteria to be genes that are p53 dependent. (B) Up−/down-regulated genes in RPS19 MO compared with the control and up−/down-regulated genes in RPS19+p53 MO compared with the control; we considered genes that satisfied the above criteria to be genes that are independent of p53.
List of p53-dependent genes.
| Gene ID | Regulation | Annotation |
| mt2 | up | metallothionein 2 |
| dnajb1b | down | DnaJ (Hsp40) homolog, subfamily B, member 1b |
| fzd5 | down | frizzled homolog 5 |
| hsp70 | down | NA |
| hsp70l | down | heat shock cognate 70-kd protein, like |
| hsp90aa1.2 | down | heat shock protein 90, alpha (cytosolic), class A member 1, tandem duplicate 2 |
| LOC562935 | down | NA |
| mal | down | mal, T-cell differentiation protein |
| pdcd4b | down | NA |
| si:dkeyp-35b8.5 | down | NA |
| zgc:136410 | down | zgc:136410 |
| zgc:174006 | down | zgc:174006 |
List of p53-independent genes.
| Gene ID | Regulation | Annotation |
| c6 | up | complement component 6 |
| cldn1 | up | claudin 1 |
| cyp24a1 | up | cytochrome P450, family 24, subfamily A, polypeptide 1 |
| cyr61l1 | up | cysteine-rich, angiogenic inducer 61 like 1 |
| fn1b | up | fibronectin 1b |
| hspb11 | up | heat shock protein, alpha-crystallin-related, b11 |
| hspb9 | up | heat shock protein, alpha-crystallin-related, 9 |
| LOC554386 | up | NA |
| mustn1 | up | NA |
| optc | up | opticin |
| pdlim3b | up | PDZ and LIM domain 3b |
| popdc1 | up | popeye domain containing 1 |
| pth1a | up | parathyroid hormone 1a |
| rn7sk | up | NA |
| scpp5 | up | NA |
| srfl | up | serum response factor like |
| tagln | up | transgelin |
| ydjc | up | NA |
| zgc:158463 | up | zgc:158463 |
| zgc:194878 | up | zgc:194878 |
| zgc:92480 | up | zgc:92480 |
| a2ml | down | alpha-2-macroglobulin-like |
| acsl5 | down | acyl-CoA synthetase long-chain family member 5 |
| akr1a1a | down | aldo-keto reductase family 1, member A1a (aldehyde reductase) |
| ambpl | down | alpha-1-microglobulin/bikunin precursor, like |
| ampd1 | down | adenosine monophosphate deaminase 1 (isoform M) |
| apom | down | NA |
| barx1 | down | BarH-like homeobox 1 |
| bhlhe23 | down | basic helix-loop-helix family, member e23 |
| calrl2 | down | calreticulin, like 2 |
| cfh | down | complement factor H |
| col10a1 | down | collagen, type X, alpha 1 |
| crx | down | cone-rod homeobox |
| cyp2aa3v1 | down | NA |
| cyp4v8 | down | cytochrome P450, family 4, subfamily V, polypeptide 8 |
| elavl4 | down | ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu antigen D) |
| f7 | down | coagulation factor VII |
| f7i | down | coagulation factor VIIi |
| fabp10a | down | fatty acid binding protein 10a, liver basic |
| gnb3a | down | NA |
| habp2 | down | hyaluronan binding protein 2 |
| hmga1b | down | high mobility group AT-hook 1b |
| hmp19 | down | HMP19 protein |
| hpda | down | 4-hydroxyphenylpyruvate dioxygenase a |
| klf11a | down | Kruppel-like factor 11a |
| krml2 | down | NA |
| lhx9 | down | LIM homeobox 9 |
| lipf | down | lipase, gastric |
| lmo3 | down | LIM domain only 3 |
| LOC561143 | down | NA |
| LOC796447 | down | NA |
| mab21l1 | down | mab-21-like 1 |
| matn1 | down | matrilin 1 |
| msrb2 | down | methionine sulfoxide reductase B2 |
| ndrg1b | down | NA |
| neurod | down | neurogenic differentiation |
| neurod6a | down | neurogenic differentiation 6a |
| neurod6b | down | neurogenic differentiation 6b |
| nfixb | down | nuclear factor I/Xb |
| nr0b2a | down | nuclear receptor subfamily 0, group B, member 2a |
| nr2e3 | down | nuclear receptor subfamily 2, group E, member 3 |
| otx2 | down | orthodenticle homolog 2 |
| otx5 | down | orthodenticle homolog 5 |
| oxct1b | down | 3-oxoacid CoA transferase 1b |
| pbx3b | down | pre-B-cell leukemia transcription factor 3b |
| pcdh1g22 | down | protocadherin 1 gamma 22 |
| pcdh1g26 | down | protocadherin 1 gamma 26 |
| pcdh8 | down | protocadherin 8 |
| pde6g | down | phosphodiesterase 6G, cGMP-specific, rod, gamma |
| pmepa1 | down | prostate transmembrane protein, androgen induced 1 |
| pygl | down | phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI) |
| rbp2a | down | retinol binding protein 2a, cellular |
| rgs5a | down | regulator of G-protein signaling 5a |
| samd7 | down | NA |
| sardh | down | sarcosine dehydrogenase |
| sema3d | down | semaphorin 3d |
| sept4a | down | septin 4a |
| serpinc1 | down | serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1 |
| serpinf1 | down | serine (or cysteine) peptidase inhibitor, clade F, member 1 |
| sfrp2 | down | secreted frizzled-related protein 2 |
| sh3bgrl2 | down | SH3 domain binding glutamic acid-rich protein like 2 |
| si:ch211-102c2.6 | down | NA |
| si:ch211-284e20.8 | down | si:ch211-284e20.8 |
| si:dkey-22i16.3 | down | NA |
| si:dkey-39n1.2 | down | NA |
| si:dkey-52k20.7 | down | si:dkey-52k20.7 |
| si:dkeyp-86e4.1 | down | NA |
| six7 | down | sine oculis homeobox homolog 7 |
| si:xx-by187g17.1 | down | NA |
| slc13a2 | down | solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 |
| slc17a5 | down | solute carrier family 17 (anion/sugar transporter), member 5 |
| slc25a36a | down | solute carrier family 25, member 36a |
| spon2b | down | spondin 2b, extracellular matrix protein |
| tfap2b | down | transcription factor AP-2 beta |
| tuba2 | down | tubulin, alpha 2 |
| uox | down | urate oxidase |
| vasa | down | vasa homolog |
| vgll4 | down | vestigial like 4 (Drosophila) |
| vmhc | down | ventricular myosin heavy chain |
| vsx1 | down | visual system homeobox 1 homolog, chx10-like |
| vtna | down | vitronectin a |
| vtnb | down | vitronectin b |
| zfpm2b | down | zinc finger protein, multitype 2b |
| zgc:103710 | down | zgc:103710 |
| zgc:158288 | down | NA |
| zgc:158291 | down | zgc:158291 |
| zgc:162825 | down | zgc:162825 |
| zgc:194131 | down | zgc:194131 |
| zgc:77439 | down | zgc:77439 |
| zgc:92411 | down | zgc:92411 |